{"success":true,"data":{"pressRelease":{"id":"158539","rtpr_id":"nNFC2N04Vf-20261001","ticker":"IXHL","exchange":"NASDAQ","all_tickers":["IXHL"],"title":"Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26","author":"Newsfile Corp","published_at":"2026-10-01T14:54:03.724Z","article_body":"Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc.\n(NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex\nHealthcare Inc. (NASDAQ: IXHL). IXHL's FY26 update moves the IHL-42X story\nfrom DReAMzz preparation into active clinical execution, with first-patient\ndosing underway and the balance sheet providing runway for at least 12 months\nof planned operations. The study is evaluating approximately 120 patients\nacross nine dose combinations and 14 U.S. sites, with completion expected in\nmid-2027. In our view, the next several quarters should be measured primarily\nby enrollment cadence, dose optimization, and whether DReAMzz supports a more\nclearly defined Phase 3 design rather than near-term P&L trends. This\nsequencing should improve confidence in dose selection and Phase 3 trial\ndesign before IXHL commits to the higher development spending associated with\nlate-stage studies.\n\nTo view the full announcement, including downloadable images, bios, and more,\nclick here (https://api.newsfilecorp.com/redirect/anMJjuXMLW).\n\nKey Takeaways:\n* IHL-42X has moved from regulatory preparation into active clinical\nexecution. DReAMzz is enrolling approximately 120 patients across nine dose\ncombinations and 14 U.S. sites, with completion expected in mid-2027. The\nstudy is specifically intended to refine the dose ratio ahead of the planned\nPhase 3 program rather than replicate RePOSA's efficacy work.\n* The balance sheet meaningfully reduces near-term financing pressure, but it\ndoes not eliminate longer-term capital requirements. IXHL had $68.4M of\nunrestricted cash as of September 24 and management says this supports at\nleast 12 months of planned spending; the 10-K also explicitly says substantial\nadditional funding will be required beyond that period.\n* Pipeline prioritization has become clearer. PSX-001 remains the principal\nsecondary clinical asset, while IHL-675A's Australian Phase 2 RA study was\nterminated due to recruitment challenges and produced insufficient data to\nassess efficacy or safety. The equity story is therefore increasingly\nconcentrated around IHL-42X and the eventual DReAMzz-to-Phase 3 transition.\n(https://api.newsfilecorp.com/redirect/24WpyIW1PP)\n\nClick image above to view full announcement.\n\nStonegate Capital Partners is a leading capital markets advisory firm\nproviding investor relations, equity research, and institutional investor\noutreach services for public companies. Our affiliate, Stonegate Capital\nMarkets (member FINRA) provides a full spectrum of investment banking services\nfor public and private companies.\n\nContacts:\n\nStonegate Capital Partners\n(214) 987-4121\ninfo@stonegateinc.com\n\nSource: Stonegate, Inc. (https://api.newsfilecorp.com/redirect/MqpPeTgqpA)\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316910","article_body_html":"","raw_payload":{"data":{"id":"nNFC2N04Vf-20261001","title":"Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26","author":"Newsfile Corp","ticker":"IXHL","created":"2026-10-01T14:54:03.724Z","tickers":["IXHL"],"exchange":"NASDAQ","article_body":"Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc.\n(NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex\nHealthcare Inc. (NASDAQ: IXHL). IXHL's FY26 update moves the IHL-42X story\nfrom DReAMzz preparation into active clinical execution, with first-patient\ndosing underway and the balance sheet providing runway for at least 12 months\nof planned operations. The study is evaluating approximately 120 patients\nacross nine dose combinations and 14 U.S. sites, with completion expected in\nmid-2027. In our view, the next several quarters should be measured primarily\nby enrollment cadence, dose optimization, and whether DReAMzz supports a more\nclearly defined Phase 3 design rather than near-term P&L trends. This\nsequencing should improve confidence in dose selection and Phase 3 trial\ndesign before IXHL commits to the higher development spending associated with\nlate-stage studies.\n\nTo view the full announcement, including downloadable images, bios, and more,\nclick here (https://api.newsfilecorp.com/redirect/anMJjuXMLW).\n\nKey Takeaways:\n* IHL-42X has moved from regulatory preparation into active clinical\nexecution. DReAMzz is enrolling approximately 120 patients across nine dose\ncombinations and 14 U.S. sites, with completion expected in mid-2027. The\nstudy is specifically intended to refine the dose ratio ahead of the planned\nPhase 3 program rather than replicate RePOSA's efficacy work.\n* The balance sheet meaningfully reduces near-term financing pressure, but it\ndoes not eliminate longer-term capital requirements. IXHL had $68.4M of\nunrestricted cash as of September 24 and management says this supports at\nleast 12 months of planned spending; the 10-K also explicitly says substantial\nadditional funding will be required beyond that period.\n* Pipeline prioritization has become clearer. PSX-001 remains the principal\nsecondary clinical asset, while IHL-675A's Australian Phase 2 RA study was\nterminated due to recruitment challenges and produced insufficient data to\nassess efficacy or safety. The equity story is therefore increasingly\nconcentrated around IHL-42X and the eventual DReAMzz-to-Phase 3 transition.\n(https://api.newsfilecorp.com/redirect/24WpyIW1PP)\n\nClick image above to view full announcement.\n\nStonegate Capital Partners is a leading capital markets advisory firm\nproviding investor relations, equity research, and institutional investor\noutreach services for public companies. Our affiliate, Stonegate Capital\nMarkets (member FINRA) provides a full spectrum of investment banking services\nfor public and private companies.\n\nContacts:\n\nStonegate Capital Partners\n(214) 987-4121\ninfo@stonegateinc.com\n\nSource: Stonegate, Inc. (https://api.newsfilecorp.com/redirect/MqpPeTgqpA)\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316910"},"type":"article","timestamp":"2026-10-01T14:54:03.763381189Z","server_sent_at_ms":1790866443763},"received_at":"2026-10-01T14:54:03.816Z","source_url":"https://www.newsfilecorp.com/release/316910"},"analysis":{"id":"147166","press_release_id":"158539","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["IHL-675A Phase 2 RA study terminated due to recruitment challenges with insufficient data on efficacy or safety","10-K discloses substantial additional funding required beyond the 12-month runway","research issued by a paid IR/advisory firm, not independent"],"eventType":"other","narrative":"Stonegate Capital Partners updated its coverage of Incannex Healthcare, describing IHL-42X as moving from preparation into active clinical execution with first-patient dosing underway in the DReAMzz study.\n\nThe trial is enrolling roughly 120 patients across nine dose combinations at 14 U.S. sites, with completion expected in mid-2027 and results intended to refine the Phase 3 design.\n\nIXHL held $68.4M in unrestricted cash as of September 24, supporting at least 12 months of planned operations, though the 10-K notes substantial additional funding will be needed. The pipeline is increasingly concentrated on IHL-42X after IHL-675A's Australian RA Phase 2 was terminated for recruitment challenges.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Paid coverage update restating DReAMzz enrollment start and 12-month runway -- monitor enrollment cadence instead."},"keyFigures":{"customDimensions":{"trial_sites":14,"cash_unrestricted":"$68.4M","dose_combinations":9,"cash_runway_months":12,"patients_enrolling":120}},"namedEntities":{"people":[],"products":["IHL-42X","PSX-001","IHL-675A"],"companies":[{"name":"Incannex Healthcare Inc.","ticker":"IXHL"},{"name":"Stonegate Capital Partners","relationship":"research/IR firm"}],"dollarAmounts":[{"amount":"$68.4M","context":"unrestricted cash as of September 24"}]},"materialImpact":{"score":2,"reasoning":"Third-party paid coverage update from Stonegate Capital Partners, not an issuer disclosure. It summarizes known clinical progress (DReAMzz enrolling, ~12 months cash runway) without new material data."},"tickerRelevance":{"others":[],"primary":"IXHL"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap biotech","eventGravity":"third-party paid research update","issuerAuthored":false,"clinicalCatalyst":"DReAMzz readout mid-2027"}},"event_type":"other","event_type_secondary":["clinical_trial"],"sentiment":"neutral","material_impact_score":2,"narrative":"Stonegate Capital Partners updated its coverage of Incannex Healthcare, describing IHL-42X as moving from preparation into active clinical execution with first-patient dosing underway in the DReAMzz study.\n\nThe trial is enrolling roughly 120 patients across nine dose combinations at 14 U.S. sites, with completion expected in mid-2027 and results intended to refine the Phase 3 design.\n\nIXHL held $68.4M in unrestricted cash as of September 24, supporting at least 12 months of planned operations, though the 10-K notes substantial additional funding will be needed. The pipeline is increasingly concentrated on IHL-42X after IHL-675A's Australian RA Phase 2 was terminated for recruitment challenges.","key_figures":{"customDimensions":{"trial_sites":14,"cash_unrestricted":"$68.4M","dose_combinations":9,"cash_runway_months":12,"patients_enrolling":120}},"named_entities":{"people":[],"products":["IHL-42X","PSX-001","IHL-675A"],"companies":[{"name":"Incannex Healthcare Inc.","ticker":"IXHL"},{"name":"Stonegate Capital Partners","relationship":"research/IR firm"}],"dollarAmounts":[{"amount":"$68.4M","context":"unrestricted cash as of September 24"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T14:54:09.431Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap biotech","eventGravity":"third-party paid research update","issuerAuthored":false,"clinicalCatalyst":"DReAMzz readout mid-2027"}},"durationMs":5601,"modelName":"glm-5.3-flashx"}}